title: Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.
abstract: Several observational studies have demonstrated that serum levels of minerals and parathyroid hormone (PTH) have U- or J-shaped associations with mortality in maintenance hemodialysis patients, but the relationship between serum alkaline phosphatase (AlkPhos) and risk for all-cause or cardiovascular death is unknown. In this study, a 3-yr cohort of 73,960 hemodialysis patients in DaVita outpatient dialysis were studied, and the hazard ratios for all-cause and cardiovascular death were higher across 20-U/L increments of AlkPhos, including within the various strata of intact PTH and serum aspartate aminotransferase. In the fully adjusted model, which accounted for demographics, comorbidity, surrogates of malnutrition and inflammation, minerals, PTH, and aspartate aminotransferase, AlkPhos > or =120 U/L was associated with a hazard ratio for death of 1.25 (95% confidence interval 1.21 to 1.29; P < 0.001). This association remained among diverse subgroups of hemodialysis patients, including those positive for hepatitis C antibody. A rise in AlkPhos by 10 U/L during the first 6 mo was incrementally associated with increased risk for death during the subsequent 2.5 yr. In summary, high levels of serum AlkPhos, especially >120 U/L, are associated with mortality among hemodialysis patients. Prospective controlled trials will be necessary to test whether serum AlkPhos measurements could be used to improve the management of renal osteodystrophy.
authors.affiliation: Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90509-2910, USA.
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Regidor
authors.forename: Csaba P
authors.initials: CP
authors.lastname: Kovesdy
authors.forename: Rajnish
authors.initials: R
authors.lastname: Mehrotra
authors.forename: Mehdi
authors.initials: M
authors.lastname: Rambod
authors.forename: Jennie
authors.initials: J
authors.lastname: Jing
authors.forename: Charles J
authors.initials: CJ
authors.lastname: McAllister
authors.forename: David
authors.initials: D
authors.lastname: Van Wyck
authors.forename: Joel D
authors.initials: JD
authors.lastname: Kopple
authors.forename: Kamyar
authors.initials: K
authors.lastname: Kalantar-Zadeh
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D016723:Bone Remodeling; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000201:enzymology / Q000209:etiology / Q000401:mortality; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000201:enzymology / Q000209:etiology / Q000401:mortality; D007676:Kidney Failure, Chronic / Q000150:complications / Q000201:enzymology / Q000401:mortality / Q000628:therapy; D008297:Male; D008903:Minerals / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D011379:Prognosis; D006435:Renal Dialysis / Q000401:mortality*; D014481:United States / Q000453:epidemiology
chemical_list: D015415:Biomarkers; D008903:Minerals; D010281:Parathyroid Hormone; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase